Recurrent Parotitis Treatment Market by 2029

Recurrent Parotitis Treatment Market to grow at a CAGR of 6% in the above mentioned forecast period

Recurrent parotitis treatment market is expected to gain market growth in the forecast period of 2022-2029. Data Bridge Market Research analyses the market to account to grow at a CAGR of 6% in the above mentioned forecast period and is expected to reach the USD 7,876.35 million by 2029.

Request For a Sample Copy of This Report @

The swelling of one or both parotid glands, which are salivary glands positioned in the cheek between the ear and jaw on each side of the head, is known as parotitis. Recurrent parotitis is a recurrent parotid inflammation that is usually linked with non-obstructive parotid gland sialectasis. Recurrent parotitis in children is also termed as juvenile recurrent parotitis. Recurrent episodes of swelling and/or pain in the parotid gland, frequently accompanied by fever and malaise, characterize this condition. It generally affects youngsters, although it can also impact adults. It’s a rare ailment, and the cause is yet unknown.

The rise in the prevalence of recurrent parotitis is the major driver resulting in the expansion of market’s growth. Another significant factor influencing the growth rate of recurrent parotitis treatment market is the rising healthcare expenditure. Furthermore, advancement in the medical technology, growing government funding and rising initiatives by public and private organisations to spread awareness are the factors that will expand the recurrent parotitis treatment market. Other factors such as increase in the level of disposable income and upsurge in the adoption rate of early genetic counseling will positively impact the recurrent parotitis treatment market’s growth rate. Additionally, improvements associated with reimbursement policies will result in the expansion of recurrent parotitis treatment market.

North America dominates the recurrent parotitis treatment market due to the presence of major key players, high disposable income and well-developed healthcare infrastructure in this region. Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to the increasing patient pool, rising investment in the healthcare sector, and growing government support.

Some of the major players operating in the recurrent parotitis treatment market are Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Sanofi, Abbott, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson Private Limited, Mylan N.V., Allergan, Merck & Co., Inc., Melinta Therapeutics LLC, Basilea Pharmaceutica Ltd., Tetraphase Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Lupin, SHIONOGI & Co., Ltd., AbbVie Inc., Cumberland Pharmaceuticals Inc., Eli Lilly and Company, Boehringer Ingelheim International GmbH, and Takeda Pharmaceutical Company Limited., among others.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:-

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475